elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q49820833-241C8DB6-9B1A-4790-8C30-5D860BB8430C
Q49820833-241C8DB6-9B1A-4790-8C30-5D860BB8430C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49820833-241C8DB6-9B1A-4790-8C30-5D860BB8430C
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
P2860
Q49820833-241C8DB6-9B1A-4790-8C30-5D860BB8430C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49820833-241C8DB6-9B1A-4790-8C30-5D860BB8430C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5e94a605dbe0ba8961cece84898417862624261a
P2860
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration.